Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Venetoclax - AbbVie/Genentech

Next Previous
X
Search
Drug Profile

Venetoclax - AbbVie/Genentech

Alternative Names: A-1195425.0; ABT 0199; ABT 199; GDC-0199; RG-7601; RO-5537382; Venclexta; VENCLYXTO; Venclyxto

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories; Genentech; Walter and Eliza Hall Institute of Medical Research
  • Developer AbbVie; Celgene Corporation; Dana-Farber Cancer Institute; Eli Lilly and Company; Emory University; Genentech; Janssen Research & Development; M. D. Anderson Cancer Center; Merck & Co; Nantes University Hospital; National Cancer Institute (USA); Nordic Lymphoma Group; Pharmacyclics; Roche; Syros Pharmaceuticals; University Health Network
  • Class Antineoplastics; Benzamides; Heterocyclic bicyclo compounds; Piperazines; Pyrans; Pyridines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia
  • Registered Acute myeloid leukaemia
  • Phase III Mantle-cell lymphoma; Myelodysplastic syndromes
  • Phase II Breast cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Phase I/II Chronic myelomonocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer
  • Phase I B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Cancer; Haematological malignancies; Non-small cell lung cancer; Small cell lung cancer
  • No development reported Systemic lupus erythematosus

Most Recent Events

  • 09 Aug 2024 Genentech initiates a phase II trial for Chronic Lymphocytic Leukemia (First-line therapy, Combination therapy) in USA (PO) (NCT06524375)
  • 05 Aug 2024 AbbVie initiates phase III trial in Chronic lymphocytic leukemia (Combination therapy, First-line therapy and greater) in US (PO) (NCT06428019) ( EudraCT2024-512147-23-00)
  • 09 Jul 2024 Hoffmann-La Roche terminates a phase I trial in Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in USA, Italy, France, Spain (IV) due to strategic prioritization (NCT04790903)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top